WAVE Life Sciences Ltd.
In the quarter to June 2026, revenue fell 73.9%, EPS fell 9.68% and free cash flow fell 17.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow WVE
WAVE Life Sciences Ltd. (WVE) EV/Sales
As of 16 October 2026, WAVE Life Sciences Ltd. (WVE) trades at a EV/Sales of 2.2×. Over the past ten years it has ranged from −0.9× (March 2022) to 1,050× (September 2016); the current reading is higher than 15% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 53.0× | 307.63% |
| FY2024 | 13.0× | 302.35% |
| FY2023 | 3.2× | (97.05%) |
| FY2022 | 110× | 45,282.92% |
| FY2021 | 0.2× | (96.09%) |
| FY2020 | 6.2× | (20.53%) |
| FY2019 | 7.8× | (89.24%) |
| FY2018 | 72.4× | (63.89%) |
| FY2017 | 200× | (51.05%) |
| FY2016 | 409× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 10.6× | (15.84%) |
| Mar 2026 | 12.6× | (76.18%) |
| Dec 2025 | 53.0× | 461.28% |
| Sep 2025 | 9.4× | 3.48% |
| 39 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| CLYM Climb Bio, Inc. compare | n/m |
| NVCT Nuvectis Pharma, Inc. compare | n/m |
| WVE WAVE Life Sciences Ltd. | 2.2× |
| PHAT Phathom Pharmaceuticals, Inc. compare | 2.4× |
| ZVRA Zevra Therapeutics, Inc. compare | 3.4× |
| SLDB Solid Biosciences Inc. compare | 37.0× |
| AVTX Avalo Therapeutics, Inc. compare | 82.3× |
| PRME Prime Medicine, Inc. compare | 128× |
| DSGN Design Therapeutics, Inc. compare | 1,934× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)